Bleeding Disorders Treatment Market Report and Forecast 2025-2034

The bleeding disorders treatment market was valued at USD 13.53 Billion in 2024 driven by advancements in gene therapy across the 8 major markets. It is expected to grow at a CAGR of 8.10% during the forecast period of 2025-2034 and attain a market value of USD 29.48 Billion by 2034

Bleeding Disorders Treatment Market Overview

Managing bleeding disorders includes reducing risk, using drugs, and receiving replacement therapy to alleviate harm. Hemophilia and other bleeding disorders result in unusual bleeding and bruising. They may be uncommon or frequent and are usually passed down in families. The rise in medical treatment progress and the shift towards gene therapy are expected to fuel market growth in the coming years.

Bleeding Disorders Treatment Market Growth Drivers

Advancements in Gene Therapy to Boost the Market Growth

Advances in gene therapy, like Pfizer's approval of gene therapy for hemophilia B in April 2024, are driving growth in the market for treating bleeding disorders. The hemophilia treatment landscape has been transformed by the introduction of groundbreaking medications such as Beqvez and Hemgenix, providing patients with a more convenient treatment choice.

Bleeding Disorders Treatment Market Trends

The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:

Rising Focus on Pediatric Care to Affect the Market Landscape Significantly

Pediatric healthcare, particularly focusing on treating bleeding disorders like hemophilia in children, is a notable trend in the market. Sanofi's endorsement of ALTUVIIIO for weekly administration underscores the commitment to creating novel therapies for children to enhance their well-being and avoid enduring issues such as joint damage.

Advancements in Medical Treatments

The growth of the bleeding disorders treatment market is being propelled by recent developments, including the FDA's approval of marstacimab-hncq (Hympavzi) for hemophilia A and B in October 2024. This inhibitor for the tissue factor pathway provides a distinct treatment choice, with simple delivery using a pre-filled auto-injector pen, meeting previously unaddressed requirements.

Rising Demand for Cost-Effective

Increasing demand for affordable hemophilia treatments emphasizes cost-effective prophylactic care, reducing healthcare costs, improving patient quality of life, and minimizing hospitalizations. This approach is now being adopted by many regions, showing a growing need for efficient bleeding disorder solutions.

Increased Focus on Prophylactic Treatments

FDA approved Hympavzi for hemophilia A and B prophylaxis in November 2024, reflecting a shift towards preventive care in bleeding disorders treatment. This innovative therapy offers safer, more consistent management for patients.

Bleeding Disorders Treatment Market Segmentation

The market report offers a detailed analysis of the market based on the following segments:

Market Breakup by Type:

• Hemophilia A
• Hemophilia B
• Von Willebrand Disease
• Others

Market Breakup by Drug Class:

• Plasma-Derived Coagulation Factor Concentrates
• Factor VIII
• Factor IX
• Factor for Von Willebrand Disease
• Activated Prothrombin Complex Concentrate
• Recombinant Coagulation Factor Concentrates
• Factor VIII
• Factor IX
• Factor for Von Willebrand Disease
• Desmopressin
• Antifibrinolytics
• Fibrin Sealants
• Others

Market Breakup by End User:

• Hospitals
• Specialty Clinics
• Others

Market Breakup by Region:

• United States
• EU-4 and the United Kingdom
• Germany
• France
• Italy
• Spain
• United Kingdom
• Japan
• India

Bleeding Disorders Treatment Market Share

Market Segmentation Based on the Type to Witness Growth

Based on the type, the market is segmented into hemophilia A, hemophilia B, von Willebrand disease, and others. Hemophilia A is a prominent blood disorder and is expected to dominate the market share. It is identified by a lack of clotting factor VIII. The patient outcomes have significantly improved due to recombinant clotting factor treatments, resulting in a greater emphasis on research and treatment options.

Bleeding Disorders Treatment Market Analysis by Region

The market report covers regions such as the US, EU-4 (Germany, France, Italy, Spain), UK, Japan, and India. Advanced medical technology adoption and pharmaceutical development are anticipated to make North America the leading regional market in the forecast period. Around 30,000 to 33,000 men in the United States suffer from hemophilia, with a majority having severe hemophilia A.

Leading Players in the Bleeding Disorders Treatment Market

The key features of the market report include patent analysis, clinical trials analysis, grant analysis, funding, and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

CSL Behring LLC

CSL Ltd, a biotechnology company, created HEMGENIX, a gene therapy for hemophilia B in July 2024, that can raise factor IX levels and decrease bleeding events in adult patients. It is approved in Canada, the US, the EU, the UK, and Switzerland.

Novo Nordisk

Novo Nordisk, a pharmaceutical company from Denmark, revealed encouraging findings from a clinical trial for Mim8, their experimental hemophilia medication in June 2024. Weekly and monthly doses were both successful in managing bleeding in individuals with type A hemophilia.

Takeda Biopharmaceuticals India Private Limited

Takeda is a patient-centered biopharmaceutical company driving R&D globally, especially in the bleeding disorders market. They focus on personalized care for rare bleeding disorders like hemophilia and von Willebrand’s disease, aiming to enhance treatment and improve patient outcomes.

Bayer AG

Bayer AG, a German multinational pharmaceutical company, is a major player in the bleeding disorders treatment market, focusing on hemophilia A and other blood disorders, with ongoing research and development efforts.

Other players in the market are Biogen Inc., Pfizer Inc., and Grifols, S.A., among others.

Key Questions Answered in the Bleeding Disorders Treatment Market Report

• What was the bleeding disorders treatment market value in 2024?
• What is the bleeding disorders treatment market forecast outlook for 2025-2034?
• What are the regional markets covered in the report?
• What is the market segmentation based on the type?
• What is the market breakup based on drug class?
• What is the market breakup based on end users?
• What are the major factors aiding the bleeding disorders treatment market demand?
• How has the market performed so far and how is it anticipated to perform in the coming years?
• What are the major drivers, opportunities, and restraints in the market?
• What are the major trends influencing the market?
• Which regional market is expected to dominate the market share in the forecast period?
• Which country is likely to experience elevated growth during the forecast period?
• Who are the key players involved in the bleeding disorders treatment market?
• What is the patent landscape of the market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

This product will be delivered within 3-5 business days.